The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) who purchased shares between June 10, 2019 and February 18, 2022. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.
(i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until May 24, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >